

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	12,710,900	12,787,400	12,801,900	12,768,200
Prediabetes	3,450,300	3,585,500	3,697,000	3,692,200
Diagnosed diabetes	1,087,900	1,296,400	1,459,200	1,571,400
Undiagnosed diabetes	358,300	405,500	433,000	441,800
Total with diabetes (diagnosed and undiagnosed)	1,446,300	1,701,900	1,892,200	2,013,200
Complications:				
Visual impairment	178,400	206,400	225,400	235,700
Renal failure	2,590	2,980	3,240	3,370
Leg amputations	2,250	2,460	2,550	2,530
Annual deaths attributable to diabetes	11,720	13,330	14,250	14,530
Total annual cost (2015 dollars)	\$15.1 B	\$17.6 B	\$19.5 B	\$20.8 B
Annual medical costs	\$11.3 B	\$13.1 B	\$14.5 B	\$15.4 B
Annual nonmedical costs	\$3.8 B	\$4.5 B	\$5.0 B	\$5.4 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	2,149,000	2,403,100	2,688,800	2,890,100
Prediabetes	1,096,000	1,225,600	1,371,300	1,473,900
Diagnosed diabetes	406,200	454,200	508,200	546,200
Undiagnosed diabetes	150,400	168,200	188,200	202,300
Total with diabetes (diagnosed and undiagnosed)	556,600	622,400	696,400	748,500
Complications:				
Visual impairment	76,000	82,800	90,300	94,500
Renal failure	1,250	1,350	1,460	1,520
Leg amputations	940	970	1,000	1,000
Annual deaths attributable to diabetes	8,080	8,930	9,260	9,150
Total annual cost (2015 dollars)	\$7.1 B	\$8.0 B	\$8.9 B	\$9.6 B
Annual medical costs	\$6.7 B	\$7.5 B	\$8.3 B	\$9.0 B
Annual nonmedical costs	\$0.4 B	\$0.5 B	\$0.6 B	\$0.6 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.